Aptamer: Turner Pope
has today issued two separate news releases. One of them covers new data that was released at the 2025 American Society for Gene and Cell Therapy (‘ASGCT’) Annual Meeting (13 - 17 May 2025) confirming Aptamer’s Optimer® delivery vehicle, which was originally developed for liver fibrosis, has also been found to be capable of targeting other similarly diseased organs, including the kidney, skin and heart. These findings substantially increase the molecule’s commercial scope, potentially positioning it as a highly adaptable therapeutic delivery system with broad applicability across fibrotic disease. They represent a further important step toward unlocking high value opportunities in areas of significant unmet medical need. The other release details the Group’s recent winning of two new fee for-service (‘FFS’) development contracts from existing customers, with a combined value of up to £231,000, along with agreement of licensing heads of terms with a global provider of specialty enzymes for developed enzyme modulating Optimers. This adds one further licensing opportunity to the ten that were presented with Aptamer’s half year results on 11 March 2025.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.